Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00532519
First received: September 19, 2007
Last updated: NA
Last verified: September 2007
History: No changes posted
  Purpose

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.


Condition Intervention
Prurigo Nodularis
Drug: citalopram (cipralex)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label

Resource links provided by NLM:


Further study details as provided by Hadassah Medical Organization:

Intervention Details:
    Drug: citalopram (cipralex)
    10-20 mg/day, for 12 weeks.
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • prurigo nodularis
  • age: 18-70 years
  • agreed to participate

Exclusion Criteria:

  • younger than 18 or older than 70
  • pregnant or lactating women
  • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.
  • sensitivity to cipralotam
  • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year
  • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532519

Locations
Israel
: Hadassah Medical Organization,
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: liran horev, md Hadassah Medical Organization
Principal Investigator: rena cooper-kazaz, md Hadassah Medical Organization
  More Information

ClinicalTrials.gov Identifier: NCT00532519     History of Changes
Other Study ID Numbers: horcoop-hmo-ctil 
Study First Received: September 19, 2007
Last Updated: September 19, 2007
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Neurodermatitis
Prurigo
Dermatitis
Skin Diseases
Skin Diseases, Eczematous
Serotonin Uptake Inhibitors
Citalopram
Dexetimide
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents

ClinicalTrials.gov processed this record on December 02, 2016